Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8898363 | 0.85 | ALDH1A1 (0.32) | FFAR1CPT2TDP1HMGCRCHRM1 | |
| SCHEMBL8897340 | 0.84 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL11974544 | 0.80 | KDM4E (0.35) | TSHR | |
| SCHEMBL818454 | 0.78 | HMGCR (0.40) | FFAR1CPT2TDP1HMGCRCHRM1 | |
| SCHEMBL2529497 | 0.78 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL7028989 | 0.78 | MAPT (0.36) | FFAR1CPT2TDP1TSHR | |
| SCHEMBL20223107 | 0.78 | — | — | |
| SCHEMBL2529495 | 0.78 | HMGCR (0.32) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL269663 | 0.78 | CES2 (0.43) | TDP1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL12424396 | 0.78 | TDP1 (0.47) | TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839657-B2 | Ionizable lipids and compositions for nucleic acid delivery | WESTGENE BIOPHARMA CO., LTD (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20170368189-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-12-28 | — | — | US | disclosed |
| US-20170121366-A1 | DIPEPTIDES AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | CORNELL UNIVERSITY | 2017-05-04 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-8785151-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-07-22 | — | — | US | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20130231260-A1 | POLYMER SCAFFOLDS FOR ASSAY APPLICATIONS | NVS Technologies, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | FFAR1 233/4885CPT2 4379/4885TDP1 3842/4885 |
| US-20170121366-A1 | DIPEPTIDES AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | DNPEP, PSMB10, DPEP1 | FFAR1 4795/4885CPT2 4701/4885TDP1 522/4885 |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | FFAR1 1641/4885CPT2 4461/4885TDP1 2194/4885 |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | HSD11B1, HSD11B2, HSD3B1 | FFAR1 583/4885CPT2 2784/4885TDP1 1390/4885 |
| US-20110282056-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP3K19, MAP3K20, MAP3K1 | FFAR1 3531/4885CPT2 4541/4885TDP1 1129/4885 |
| US-11839657-B2 | Ionizable lipids and compositions for nucleic acid delivery | POLRMT, POLN, NPC1L1 | FFAR1 1543/4885CPT2 1474/4885TDP1 692/4885 |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | FFAR1 2509/4885CPT2 4358/4885TDP1 1348/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | FFAR1 3441/4885CPT2 1916/4885TDP1 910/4885 |
| US-20110071142-A1 | IDENTIFICATION AND USE OF SMALL MOLECULES TO MODULATE TRANSCRIPTION FACTOR FUNCTION AND TO TREAT TRANSCRIPTION FACTOR ASSOCIATED DISEASES | CREBBP, TEAD1, SREBF1 | FFAR1 4115/4885CPT2 3318/4885TDP1 1906/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | FFAR1 496/4885CPT2 4150/4885TDP1 1935/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | FFAR1 4433/4885CPT2 1679/4885TDP1 782/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | FFAR1 357/4885CPT2 3334/4885TDP1 3649/4885 |
| US-20170368189-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | FFAR1 1199/4885CPT2 3058/4885TDP1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.